Pre-made Abagovomab benchmark antibody (Whole mAb, anti-CA125/MUC16 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is hoped that the body's immune system may be able to combat any remaining individual tumour cells and thus prevent recurrence of the disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-001-1mg	1mg	3090
GMP-Bios-ab-001-10mg	10mg	Inquiry
GMP-Bios-ab-001-100mg	100mg	Inquiry
GMP-Bios-ab-001-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody
INN Name	Abagovomab
Target	MUC16
Format	Whole mAb
Derivation	Mouse
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	Menarini
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Ovarian cancer;Pancreatic cancer
Development Tech	na